scispace - formally typeset
H

Hubert G. M. Leufkens

Researcher at Utrecht University

Publications -  552
Citations -  24739

Hubert G. M. Leufkens is an academic researcher from Utrecht University. The author has contributed to research in topics: Population & Odds ratio. The author has an hindex of 74, co-authored 538 publications receiving 22557 citations. Previous affiliations of Hubert G. M. Leufkens include European Medicines Agency & University of Southampton.

Papers
More filters
Journal ArticleDOI

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.

TL;DR: It is concluded that oral corticosteroid treatment using more than 5 mg (of prednisolone or equivalent) daily leads to a reduction in bone mineral density and a rapid increase in the risk of fracture during the treatment period.
Journal ArticleDOI

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.

TL;DR: The objective of this study is to examine the level of concordance of the various estimates to the measure used by the WHO Collaborating Centre for International ADR monitoring, the information component (IC), when applied to the dataset of the Netherlands Pharmacovigilance Foundation Lareb.
Journal ArticleDOI

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

TL;DR: The findings suggest that the adverse skeletal effects of oral corticosteroids manifest rapidly and are related to daily dose, and Preventive measures against cortICosteroid-induced osteoporosis should be instituted as soon after the commencement of glucocorticoid therapy as possible.
Journal ArticleDOI

Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis

TL;DR: Patients with rheumatoid arthritis are at increased risk of osteoporotic fractures, which is attributable to a combination of disease activity and use of oral glucocorticoids.
Journal ArticleDOI

Dronedarone in High-Risk Permanent Atrial Fibrillation

TL;DR: Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events and should not be used in such patients.